188 related articles for article (PubMed ID: 36685586)
21. Drug-aggravated Bullous Pemphigoid in a 47-year-old Asian Woman - A Case Report.
Nelramachandrakumar D; Hariharan H; Nagamanickam S; Chander J SJU
Curr Drug Saf; 2023; 18(3):379-382. PubMed ID: 35593331
[TBL] [Abstract][Full Text] [Related]
22. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
23. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
[TBL] [Abstract][Full Text] [Related]
24. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
[TBL] [Abstract][Full Text] [Related]
25. Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Sadik CD; Langan EA; Gutzmer R; Fleischer MI; Loquai C; Reinhardt L; Meier F; Göppner D; Herbst RA; Zillikens D; Terheyden P
Front Immunol; 2020; 11():588582. PubMed ID: 33708189
[TBL] [Abstract][Full Text] [Related]
26. A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung.
Das A; Das S; Das SK; Basuthakur S
J Postgrad Med; 2015; 61(3):197-9. PubMed ID: 26119440
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid.
Sun L; Wang C; Wu C; Zhou Y; Wang C
Ann Pharmacother; 2022 Feb; 56(2):205-212. PubMed ID: 34105395
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
29. A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report.
Gresham LM; Kirchhof MG
SAGE Open Med Case Rep; 2023; 11():2050313X231160926. PubMed ID: 36968984
[TBL] [Abstract][Full Text] [Related]
30. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
[TBL] [Abstract][Full Text] [Related]
31. A case report of paraneoplastic bullous pemphigoid associated with mantle cell lymphoma: A rare presentation.
Md Radzi AB; Kasim SS
Medicine (Baltimore); 2023 Jan; 102(4):e32822. PubMed ID: 36705376
[TBL] [Abstract][Full Text] [Related]
32. Erythrodermic Bullous Pemphigoid in Skin of Color Treated With Dupilumab.
Sanfilippo E; Gonzalez Lopez A; Saardi KM
J Drugs Dermatol; 2023 Jul; 22(7):685-686. PubMed ID: 37410035
[TBL] [Abstract][Full Text] [Related]
33. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
34. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
[TBL] [Abstract][Full Text] [Related]
35. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
36. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
Fisler RE; Saeb M; Liang MG; Howard RM; McKee PH
Am J Dermatopathol; 2003 Jun; 25(3):183-9. PubMed ID: 12775979
[TBL] [Abstract][Full Text] [Related]
37. "Half-half" blisters in bullous pemphigoid successfully treated with adjuvant high-dose intravenous immunoglobulin.
Pacheco D; Lopes L; Soares-Almeida L; Marques MS; Filipe P
Acta Dermatovenerol Alp Pannonica Adriat; 2012 Sep; 21(3):59-61. PubMed ID: 23267874
[TBL] [Abstract][Full Text] [Related]
38. Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
Mazumder A; Darji K; Smith K; Guo M
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593610
[TBL] [Abstract][Full Text] [Related]
39. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
40. A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma.
Tanaka A; Fujimura Y; Fuke S; Izumi K; Ujiie H
J Dermatol; 2023 Sep; 50(9):1199-1202. PubMed ID: 37122191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]